CHINA NT PHARMA GROUP COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.034 HKD | -90.29% |
|
-90.29% | -93.82% |
| Sales 2022 | 207M 28.5M 223M 2.38B | Sales 2023 | 7.37M 1.01M 7.92M 84.61M | Capitalization | 132M 18.17M 142M 1.52B |
|---|---|---|---|---|---|
| Net income 2022 | -66M -9.08M -70.95M -758M | Net income 2023 | -144M -19.81M -155M -1.65B | EV / Sales 2022 | 4.69 x |
| Net Debt 2022 | 821M 113M 882M 9.43B | Net Debt 2023 | 343M 47.25M 369M 3.94B | EV / Sales 2023 | 64.5 x |
| P/E ratio 2022 |
-2.27
x | P/E ratio 2023 |
-0.69
x | Employees | 16 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -90.29% | ||
| 1 week | -90.29% | ||
| Current month | -90.29% | ||
| 1 month | -84.55% | ||
| 3 months | -84.55% | ||
| 6 months | -93.82% | ||
| Current year | -93.82% |
1 week
0.03
0.37
1 month
0.030.43
Current year
0.030.59
1 year
0.031.02
3 years
0.034.30
5 years
0.039.20
10 years
0.0332.40
| Managers | Title | Age | Since |
|---|---|---|---|
Tit Ng
CEO | Chief Executive Officer | 60 | 01/95/01 |
Jing Fang
DFI | Director of Finance/CFO | 55 | 27/19/27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yu Biao Zhao
BRD | Director/Board Member | 54 | 31/19/31 |
Tit Ng
CEO | Chief Executive Officer | 60 | 01/95/01 |
Yu Chin
FOU | Founder | 60 | 01/95/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 114 M€ | +7.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/24/05 | 0.365 | +7.35% | 0 |
| 04/24/04 | 0.34 | +1.49% | 0 |
| 03/24/03 | 0.335 | -1.47% | 0 |
| 02/24/02 | 0.34 | -2.86% | 1,296,400 |
| 28/24/28 | 0.35 | -10.26% | 2,701,450 |
Delayed Quote Hong Kong S.E., July 02, 2024 at 01:38 pm IST
More quotes
China NT Pharma Group Co Ltd is an investment holding company principally engaged in the research and development, production and sales of pharmaceutical products. The Company mainly provides development, distribution and agency services for sales of proprietary pharmaceutical products. The Company operates its bone health digital medicine platform by providing customized health package including bone health products, equipment and rehabilitation products. In addition, the Company engages in the investment in drugs and pharmaceutical companiesâ equity as well as provision of marketing and promotion services to suppliers.
Sector
-
Calendar
28/08/2024
- Q2 2024 Earnings Release (Projected)
- Stock Market
- Equities
- 1011 Stock
